Condition: Relapsed/refractory Lymphoma · Relapsed/Refractory Leukemia · Sponsor: Affiliated Hospital of Nantong University
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
This description comes directly from the study's public registry record.
Hong Liu, MD · +86-13951300660 · hongliu63@126.com
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Nantong University | Nantong, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756321